Drugs / REGN5668
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04590326 | Dec 2020 → Nov 2028 expected | endometrial cancer, fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-12-07 | Regeneron Pharmaceuticals | Results Regeneron to Share Progress of Novel Combination Therapies in Oncology at ESMO IO regeneron.com ↗
Per initial results to be shared at ESMO IO, a combination of REGN5668 with Libtayo showed early clinical activity in patients with recurrent ovarian cancer. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-12-07 | Regeneron Pharmaceuticals | Regeneron to Share Progress of Novel Combination Therapies in Oncology at ESMO IO regeneron.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REGN5668 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04590326 ↗ |